Federal Reserve Cuts Rates, Signals Further Easing Amid Shifting Economic Outlook
Key Takeaways The Federal Reserve implemented a quarter-point interest rate cut, lowering the federal funds rate target range, with market […]
Federal Reserve Cuts Key Interest Rate by 25 Bps Amid Economic Slowdown; IPO Market Buzzes
Key Takeaways The Federal Reserve executed its first interest rate cut of 2025, lowering the benchmark federal funds rate by
U.S. Markets Tread Cautiously in Afternoon Trading as Fed Rate Cut Looms
U.S. equity markets are exhibiting a mixed performance in afternoon trading on Wednesday, September 17, 2025, as investors remain in
Market Movers: Nvidia’s AI Bet Fuels Unicorn, Refinance Rush Ignites Housing, and Trump Challenges Europe on Russia Sanctions
Key Takeaways AI startup Reflection AI secured a massive $500 million investment from Nvidia (NVDA), propelling its valuation to over
Financial Markets Buzz: GM Eyes China Revival, Eric Trump’s Crypto Empire, and Key Regulatory Scrutiny
Automotive Sector: GM Re-evaluates China Strategy General Motors (GM) is reportedly engaged in preliminary discussions to renew its longstanding joint
Deutsche Bank’s DWS Initiates Sale of Data Centre Business as GM and SAIC Discuss China Partnership Renewal
Key Takeaways DWS, the asset management arm of Deutsche Bank (DB), has commenced the sale of its data centre business,
Global Markets React to Key Economic and Tech Developments
Key Takeaways Ghana's central bank significantly cut its benchmark interest rate by 350 basis points to 21.5% from 25%, signaling
Wall Street Holds Breath Midday as Fed Rate Cut Looms; Tech Giants Face Headwinds
The U.S. stock market is exhibiting a cautious and mixed performance midday on Wednesday, September 17, 2025, as investors eagerly
Market Movers: Eli Lilly’s Obesity Drug Triumph, Tesla FSD Woes, and Economic Shifts
Key Takeaways Eli Lilly's (LLY) experimental obesity pill demonstrated superior efficacy against Novo Nordisk's (NVO) oral drug in a head-to-head
Financial Markets Brace for Fed Remarks Amid Key Economic and Corporate Developments
Key Takeaways Eli Lilly's (LLY) oral GLP-1 drug, Orforglipron, demonstrated superior efficacy over oral semaglutide in the ACHIEVE-3 trial, achieving